RESUMO
With a view to obtaining human monoclonal antibodies against HIV-1 antigens we used the Epstein-Barr virus immortalization technique to induce lymphoblastoid cell lines from peripheral blood lymphocytes of 10 people who were seropositive for HIV-1 and had no clinical symptoms. A number of polyclonal lines were obtained which synthesized antibodies against most of the major proteins and glycoproteins of HIV-1. Three stable clones were characterized for class, secretion characteristics and specificity. Two of these clones produce antibodies which react with gp41, and the third reacts with p25. One of the anti-gp41 antibodies was found to have neutralizing activity.
Assuntos
Anticorpos Monoclonais/biossíntese , Anticorpos Anti-HIV/biossíntese , Proteína gp41 do Envelope de HIV/imunologia , Soropositividade para HIV/imunologia , HIV-1/imunologia , Proteínas do Core Viral/imunologia , Sequência de Aminoácidos , Especificidade de Anticorpos , Linfócitos B/imunologia , Western Blotting , Linhagem Celular Transformada , Homólogo 5 da Proteína Cromobox , Ensaio de Imunoadsorção Enzimática , Imunofluorescência , Anticorpos Anti-HIV/análise , Anticorpos Anti-HIV/imunologia , Antígenos HIV/imunologia , Herpesvirus Humano 4/fisiologia , Humanos , Imunoglobulina G/biossíntese , Imunoglobulina G/imunologia , Dados de Sequência Molecular , Ensaio de RadioimunoprecipitaçãoAssuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Anticorpos Monoclonais , Antígenos de Grupos Sanguíneos/imunologia , Tipagem e Reações Cruzadas Sanguíneas/métodos , Antígenos do Grupo Sanguíneo de Lewis/imunologia , Sistema do Grupo Sanguíneo P/imunologia , Animais , Reações Antígeno-Anticorpo , Gatos , Cães , Testes de Hemaglutinação , Humanos , Indicadores e Reagentes , Pan troglodytes , Coelhos , OvinosRESUMO
Human monoclonal antibodies will be essential in medicine. They are valuable tools for biological diagnosis and therapeutics. Our model, human monoclonal antibodies directed against the Rhesus D antigen can be used for the determination of the Rhesus D phenotype and for the suppression of Rh(D) immunisation in women. These new products require new procedures of preparation, new regulations for the quality controls, which will be discussed in this paper.
